Company signed agreement with the West Cancer Center &amp; Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CAESAREA, Israel,

<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Company signed agreement with the West Cancer Center &amp; Research Institute, the first clinical site for its post-marketing study for ProSense&#xAE; cryoablation in the treatment of low-risk breast cancer </i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">CAESAREA, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">July 27, 2026</span> /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ICCM">ICCM</a>) (&#34;IceCure,&#34; &#34;IceCure Medical&#34; or the &#34;Company&#34;), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center &amp; Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company&#39;s post-marketing study &#34;<a xmlns="http://www.w3.org/1999/xhtml" href="https://clinicaltrials.gov/study/NCT07629206?cond=breast%20cancer&amp;viewType=Card&amp;intr=cryoablation&amp;page=2&amp;rank=13" target="_blank" rel="nofollow">ChoICE</a>,&#34; (the &#34;ChoICE Study&#34;), for ProSense&#xAE; in the treatment of low-risk breast cancer following U.S Food and Drug Administration  (&#34;FDA&#34;) marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across 30 U.S. sites, gathering real-world data to support further clinical adoption and broader access for eligible patients.</p>
<div xmlns="http://www.w3.org/1999/xhtml" id="prni_dvprnejpg64d0left" dir="ltr" style="width: 100%; text-align: left;"><img xmlns="http://www.w3.org/1999/xhtml" id="prnejpg64d0left" style="width: 400px; height: 200px;" title="IceCure Medical Logo" src="https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg" alt="IceCure Medical Logo" align="middle"></img></div><p xmlns="http://www.w3.org/1999/xhtml">&#34;We are pleased to welcome West Cancer Center &amp; Research Institute to the ChoICE Study,&#34; said Eyal Shamir, Chief Executive Officer of IceCure Medical. &#34;We believe each new site adds important momentum as we work with leading clinical teams across the U.S. to expand real-world experience with ProSense&#xAE; and support broader access to minimally invasive cryoablation for eligible breast cancer patients.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">The ChoICE Study builds on the Company&#39;s clinical efforts in breast cancer cryoablation, demonstrating its ongoing commitment to advancing evidence-based care for leading cancer diagnosis in women globally.</p><p xmlns="http://www.w3.org/1999/xhtml">The site will be led by Dr. Richard Gilmore, MD, MBA, DipABLM, a breast surgical oncologist at the Margaret West Comprehensive Breast Center, part of West Cancer Center &amp; Research Institute.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About the ChoICE Study</b></p><p xmlns="http://www.w3.org/1999/xhtml">The ChoICE Study will evaluate ProSense&#xAE; cryoablation with endocrine therapy for low-risk, early-stage breast cancer in patients aged 70 years and above.</p><p xmlns="http://www.w3.org/1999/xhtml">ProSense&#xAE; is cleared by the U.S. Food and Drug Administration (&#34;FDA&#34;) for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. The ChoICE Study aims to generate additional real-world data regarding the use of ProSense&#xAE; in this indication.</p><p xmlns="http://www.w3.org/1999/xhtml">Under the approved study design, 30 participating sites will serve both as ChoICE Study sites and as active commercial sites, enabling them to enroll and treat a total of 400 patients while also offering ProSense&#xAE; cryoablation to appropriate patients who are not participating in the ChoICE Study. This dual pathway expands access to breast cancer cryoablation and reflects increasing interest from eligible patients seeking a minimally invasive alternative outside the study setting.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About IceCure Medical</b></p><p xmlns="http://www.w3.org/1999/xhtml">IceCure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ICCM">ICCM</a>) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company&#39;s flagship ProSense&#xAE; system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About West Cancer Center &amp; Research Institute</b></p><p xmlns="http://www.w3.org/1999/xhtml">West Cancer Center &amp; Research Institute has proudly served the Mid-South for 47 years and continues as the leader in adult cancer care. Recognized for their talented team of oncology specialists, state-of-the-art technology, robust clinical trial program and personalized approach to care, West is committed to achieving the most positive outcomes and preserving quality of life.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the &#34;safe harbor&#34; created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as &#34;believe,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;should,&#34; &#34;could,&#34; &#34;seek,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;goal,&#34; &#34;estimate,&#34; &#34;anticipate&#34; or other comparable terms. For example, the Company is using forward-looking statements when it discusses the West Cancer Center &amp; Research Institute serving as the first U.S. clinical site for the ChoICE Study; the progress of the ChoICE Study; the enrollment and treatment of up to 400 patients across 30 U.S. clinical sites; the ability of participating sites to serve both as ChoICE Study centers and active commercial sites and to offer ProSense&#xAE; cryoablation to eligible patients who are not participating in the ChoICE Study; the potential for the ChoICE Study and the resulting data to support clinical and commercial adoption of ProSense&#xAE; and broader patient access; and the Company&#39;s efforts to expand real-world experience with ProSense&#xAE; and access to minimally invasive cryoablation for eligible breast cancer patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company&#39;s planned level of revenues and capital expenditures; the Company&#39;s available cash and its ability to obtain additional funding; the Company&#39;s ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company&#39;s ability to maintain its relationships with suppliers, distributors and other partners; the Company&#39;s ability to maintain or protect the validity of its patents and other intellectual property; the Company&#39;s ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company&#39;s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC&#39;s website, <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov" rel="nofollow">www.sec.gov</a>. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investor Contact</b></p><p xmlns="http://www.w3.org/1999/xhtml">Meir Peleg<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investors@icecure-medical.com" target="_blank" rel="nofollow">investors@icecure-medical.com</a><br xmlns="http://www.w3.org/1999/xhtml"></br><span xmlns="http://www.w3.org/1999/xhtml">+1-888-902-5716</span></p><p xmlns="http://www.w3.org/1999/xhtml">Logo - <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN12512&amp;sd=2026-07-27"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breast-cancer-treatment-at-first-us-clinical-site-302835190.html" target="_blank">https://www.prnewswire.com/news-releases/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breast-cancer-treatment-at-first-us-clinical-site-302835190.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE IceCure Medical</p>

ICCM

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

IceCure kicks off U.S. ChoICE post-marketing study with first site

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Company signed agreement with the West Cancer Center &amp;amp; Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CAESAREA, Israel,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>IceCure Medical announced West Cancer Center &amp; Research Institute as the first U.S. site for its ChoICE post-marketing study of ProSense cryoablation in low-risk breast cancer. The study will enroll up to 400 patients across 30 U.S. sites, generating real-world data to support broader clinical adoption and patient access, potentially fueling near-term demand and longer-term growth.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>IceCure names West Cancer Center as first U.S. ChoICE site for ProSense.</li><li>ChoICE to enroll up to 400 patients across 30 U.S. sites.</li><li>FDA cleared ProSense for 70+ low-risk tumors ≤1.5 cm in Oct 2025.</li><li>Sites will serve as ChoICE centers and active commercial sites.</li><li>ChoICE aims to expand real-world data and broader access.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>IceCure Medical Ltd (ICCM)</strong>: Announces first U.S. ChoICE site; could expand near-term adoption and data generation.</li><li><strong>West Cancer Center &amp; Research Institute (Private)</strong>: First U.S. clinical site; collaboration strengthens real-world evidence and access.</li><li><strong>ChoICE Study (N/A)</strong>: Post-marketing study underpinning ProSense adoption; real-world data channel for growth.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: details a corporate clinical development that could influence adoption and revenue potential for ICCM.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>First U.S. ChoICE site signals near-term execution progress.</li><li>Enrollment target of 400 patients across 30 sites could drive data-driven adoption.</li><li>Dual-use path (study and commercial) may accelerate near-term utilization.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: July 27, 2026; IceCure announces West Cancer Center as first U.S. ChoICE site.</li><li>ChoICE study to enroll up to 400 patients across 30 U.S. sites.</li><li>FDA marketing authorization for ProSense granted in October 2025.</li><li>ProSense indication: 70+ with biologically low-risk tumors ≤1.5 cm on endocrine therapy.</li><li>30 sites will serve as both ChoICE study centers and active commercial sites.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Positive ChoICE tempo may lift ProSense demand and ICCM valuation over the next 12–24 months.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Company signed agreement with the West Cancer Center &amp; Research Institute, the first clinical site for its post-marketing study for ProSense&#xAE; cryoablation in the treatment of low-risk breast cancer </i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">CAESAREA, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">July 27, 2026</span> /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ICCM">ICCM</a>) (&#34;IceCure,&#34; &#34;IceCure Medical&#34; or the &#34;Company&#34;), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center &amp; Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company&#39;s post-marketing study &#34;<a xmlns="http://www.w3.org/1999/xhtml" href="https://clinicaltrials.gov/study/NCT07629206?cond=breast%20cancer&amp;viewType=Card&amp;intr=cryoablation&amp;page=2&amp;rank=13" target="_blank" rel="nofollow">ChoICE</a>,&#34; (the &#34;ChoICE Study&#34;), for ProSense&#xAE; in the treatment of low-risk breast cancer following U.S Food and Drug Administration  (&#34;FDA&#34;) marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across 30 U.S. sites, gathering real-world data to support further clinical adoption and broader access for eligible patients.</p>
<div xmlns="http://www.w3.org/1999/xhtml" id="prni_dvprnejpg64d0left" dir="ltr" style="width: 100%; text-align: left;"><img xmlns="http://www.w3.org/1999/xhtml" id="prnejpg64d0left" style="width: 400px; height: 200px;" title="IceCure Medical Logo" src="https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg" alt="IceCure Medical Logo" align="middle"></img></div><p xmlns="http://www.w3.org/1999/xhtml">&#34;We are pleased to welcome West Cancer Center &amp; Research Institute to the ChoICE Study,&#34; said Eyal Shamir, Chief Executive Officer of IceCure Medical. &#34;We believe each new site adds important momentum as we work with leading clinical teams across the U.S. to expand real-world experience with ProSense&#xAE; and support broader access to minimally invasive cryoablation for eligible breast cancer patients.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">The ChoICE Study builds on the Company&#39;s clinical efforts in breast cancer cryoablation, demonstrating its ongoing commitment to advancing evidence-based care for leading cancer diagnosis in women globally.</p><p xmlns="http://www.w3.org/1999/xhtml">The site will be led by Dr. Richard Gilmore, MD, MBA, DipABLM, a breast surgical oncologist at the Margaret West Comprehensive Breast Center, part of West Cancer Center &amp; Research Institute.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About the ChoICE Study</b></p><p xmlns="http://www.w3.org/1999/xhtml">The ChoICE Study will evaluate ProSense&#xAE; cryoablation with endocrine therapy for low-risk, early-stage breast cancer in patients aged 70 years and above.</p><p xmlns="http://www.w3.org/1999/xhtml">ProSense&#xAE; is cleared by the U.S. Food and Drug Administration (&#34;FDA&#34;) for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. The ChoICE Study aims to generate additional real-world data regarding the use of ProSense&#xAE; in this indication.</p><p xmlns="http://www.w3.org/1999/xhtml">Under the approved study design, 30 participating sites will serve both as ChoICE Study sites and as active commercial sites, enabling them to enroll and treat a total of 400 patients while also offering ProSense&#xAE; cryoablation to appropriate patients who are not participating in the ChoICE Study. This dual pathway expands access to breast cancer cryoablation and reflects increasing interest from eligible patients seeking a minimally invasive alternative outside the study setting.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About IceCure Medical</b></p><p xmlns="http://www.w3.org/1999/xhtml">IceCure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ICCM">ICCM</a>) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company&#39;s flagship ProSense&#xAE; system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About West Cancer Center &amp; Research Institute</b></p><p xmlns="http://www.w3.org/1999/xhtml">West Cancer Center &amp; Research Institute has proudly served the Mid-South for 47 years and continues as the leader in adult cancer care. Recognized for their talented team of oncology specialists, state-of-the-art technology, robust clinical trial program and personalized approach to care, West is committed to achieving the most positive outcomes and preserving quality of life.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the &#34;safe harbor&#34; created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as &#34;believe,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;should,&#34; &#34;could,&#34; &#34;seek,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;goal,&#34; &#34;estimate,&#34; &#34;anticipate&#34; or other comparable terms. For example, the Company is using forward-looking statements when it discusses the West Cancer Center &amp; Research Institute serving as the first U.S. clinical site for the ChoICE Study; the progress of the ChoICE Study; the enrollment and treatment of up to 400 patients across 30 U.S. clinical sites; the ability of participating sites to serve both as ChoICE Study centers and active commercial sites and to offer ProSense&#xAE; cryoablation to eligible patients who are not participating in the ChoICE Study; the potential for the ChoICE Study and the resulting data to support clinical and commercial adoption of ProSense&#xAE; and broader patient access; and the Company&#39;s efforts to expand real-world experience with ProSense&#xAE; and access to minimally invasive cryoablation for eligible breast cancer patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company&#39;s planned level of revenues and capital expenditures; the Company&#39;s available cash and its ability to obtain additional funding; the Company&#39;s ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company&#39;s ability to maintain its relationships with suppliers, distributors and other partners; the Company&#39;s ability to maintain or protect the validity of its patents and other intellectual property; the Company&#39;s ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company&#39;s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC&#39;s website, <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov" rel="nofollow">www.sec.gov</a>. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investor Contact</b></p><p xmlns="http://www.w3.org/1999/xhtml">Meir Peleg<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investors@icecure-medical.com" target="_blank" rel="nofollow">investors@icecure-medical.com</a><br xmlns="http://www.w3.org/1999/xhtml"></br><span xmlns="http://www.w3.org/1999/xhtml">+1-888-902-5716</span></p><p xmlns="http://www.w3.org/1999/xhtml">Logo - <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN12512&amp;sd=2026-07-27"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breast-cancer-treatment-at-first-us-clinical-site-302835190.html" target="_blank">https://www.prnewswire.com/news-releases/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breast-cancer-treatment-at-first-us-clinical-site-302835190.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE IceCure Medical</p>

IceCure Medical announced West Cancer Center & Research Institute as the first U.S. site for its ChoICE post-marketing study of ProSense cryoablation in low-risk breast cancer. The study will enroll up to 400 patients across 30 U.S. sites, generating real-world data to support broader clinical adoption and patient access, potentially fueling near-term demand and longer-term growth.

News insight

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

AI summary

Sentiment rationale

Key facts

Industry News